Abbott's XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in
22 September 2009 - 1:00AM
PR Newswire (US)
- Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major
Adverse Cardiac Events (MACE) at Three Years and a 43 Percent
Reduction vs. TAXUS - No Additional Stent Thrombosis between Two
and Three Years, and Impressive Low Rate of Very Late Stent
Thrombosis for XIENCE V SAN FRANCISCO, Sept. 21
/PRNewswire-FirstCall/ -- Long-term data presented today from the
SPIRIT III pivotal U.S. clinical trial demonstrated that the
observed clinical advantages of Abbott's market-leading XIENCE V
Everolimus Eluting Coronary Stent System continued to increase as
compared to the TAXUS Express2 Paclitaxel-Eluting Coronary Stent
System (TAXUS). At three years, XIENCE V demonstrated a 43 percent
reduction in the risk of major adverse cardiac events (MACE)
compared to TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for
TAXUS, p-value=0.003)*. MACE is an important composite clinical
measure of safety and efficacy outcomes for patients, defined as
cardiac death, heart attack (myocardial infarction or MI), or
ischemia-driven target lesion revascularization (ID-TLR driven by
lack of blood supply). The three-year results from the SPIRIT III
trial will be presented today by Gregg W. Stone, M.D., professor of
medicine at Columbia University Medical Center, during the 2009
Transcatheter Cardiovascular Therapeutics (TCT) conference in San
Francisco. "The SPIRIT III results clearly demonstrate that at
three years, patients continue to benefit from having been treated
with the XIENCE V stent rather than the TAXUS stent, with fewer
repeat cardiac procedures and fewer heart attacks in patients who
received XIENCE V," said Dr. Stone, who is also immediate past
chairman of the Cardiovascular Research Foundation, New York; and
principal investigator of the SPIRIT III trial. XIENCE V
demonstrated an impressive low rate of very late stent thrombosis
(one to three years) with no additional events between two and
three years. Per protocol, XIENCE V demonstrated a 0.2 percent**
very late stent thrombosis rate compared to 1.0 percent for TAXUS
(p-value=0.10) at three years. Per Academic Research Consortium
(ARC) definition of definite/probable stent thrombosis, the rate of
very late stent thrombosis at three years was 0.3 percent** for
XIENCE V and 1.0 percent for TAXUS (p-value=0.34). The ARC
definitions of stent thrombosis were developed to eliminate
variability in the definitions across various drug eluting stent
trials. Key Results from SPIRIT III In the 1,002-patient SPIRIT III
trial, XIENCE V demonstrated the following key results out to three
years: -- A 43 percent reduction in the risk of MACE compared to
TAXUS (9.1 percent for XIENCE V vs. 15.7 percent for TAXUS,
p-value=0.003). -- A 43 percent reduction in the risk of Target
Lesion Failure (TLF) compared to TAXUS (8.3 percent for XIENCE V
vs. 14.4 percent for TAXUS, p-value=0.005). TLF is a composite
measure of important efficacy and safety outcomes for patients,
defined as cardiac death, target vessel MI and TLR. -- A 30 percent
reduction in the risk of Target Vessel Failure (TVF) compared to
TAXUS (13.5 percent for XIENCE V vs. 19.2 percent for TAXUS,
p-value=0.03). TVF is a composite clinical measure of safety and
efficacy outcomes defined as cardiac death, MI or ischemia-driven
target vessel revascularization (TVR). -- A 42 percent reduction in
the risk of heart attacks (MI) compared to TAXUS (3.7 percent for
XIENCE V vs. 6.3 percent for TAXUS, p-value=0.07). -- A 39 percent
reduction in the risk of ID-TLR compared to TAXUS (5.4 percent for
XIENCE V vs. 8.9 percent for TAXUS, p-value=0.05). -- Per protocol
definition, a 0.2 percent** rate of very late stent thrombosis
compared to 1.0 percent for TAXUS (p-value=0.10). Per ARC
definition of definite/probable stent thrombosis, the rate of very
late stent thrombosis was 0.3 percent** for XIENCE V and 1.0
percent for TAXUS (p-value=0.34). Consistent Results in SPIRIT III
Subgroup Analyses In addition to the positive three-year results
for the overall study presentation, subgroup analyses from the
SPIRIT III trial demonstrated evidence of the strong performance by
XIENCE V in a variety of patients and lesion types that represent
complex patients. In patients with diabetes, the analysis showed
there was no difference at three years in MACE between XIENCE V and
TAXUS (11.0 percent for XIENCE V vs. 10.3 percent in TAXUS)*** . In
fact, XIENCE V maintained a consistent rate of clinical events
after the first year (8.7 percent MACE at one year and 11.0 percent
MACE at three years), whereas TAXUS demonstrated a sustained upward
trend in clinical events from one year to three years (4.7 percent
MACE at one year and 10.3 percent MACE at three years). In patients
without diabetes, the MACE rate for TAXUS at three years was more
than double the MACE rate for XIENCE V at three years (9.1 percent
for XIENCE V vs. 18.7 percent for TAXUS). "The SPIRIT III data
clearly show that XIENCE V performs in a consistent manner, with
clinical benefits continuing to improve over time compared to
TAXUS," said Robert Hance, senior vice president, vascular, Abbott.
"We are pleased to begin this year's TCT conference with a strong
showing of data for Abbott's market-leading XIENCE V, and look
forward to presenting the highly anticipated SPIRIT IV one-year
results later this week, which should provide physicians with
additional valuable insights." One-year results from the company's
SPIRIT IV trial will be presented on Wednesday, Sept. 23, during
the first late-breaking clinical trials session of the TCT
conference. The SPIRIT IV trial is one of the largest randomized
clinical trials between two drug eluting stents, with 3,690
patients enrolled, including more than 1,000 patients with
diabetes. The study results will provide valuable information about
the efficacy and safety of XIENCE V compared to TAXUS. The SPIRIT
III trial was not designed to analyze statistical differences in
any of the patient subgroups, as the sample sizes were too small to
draw firm conclusions. About the SPIRIT III Trial SPIRIT III is a
prospective, multi-center, randomized, single-blind, controlled
clinical trial comparing XIENCE V to TAXUS in 1,002 patients (669
XIENCE V patients, 333 TAXUS patients) with either one or two de
novo coronary artery lesions. The trial was conducted across 65
academic and community-based centers in the United States between
June 22, 2005, and March 15, 2006. The primary endpoint of the
SPIRIT III trial was in-segment late loss at eight months, wherein
XIENCE V demonstrated superiority to TAXUS with a statistically
superior 50 percent reduction in late loss (mean, 0.14 mm for
XIENCE V vs. 0.28 mm for TAXUS, p-value =0.004). In-segment late
loss is a measure of vessel re-narrowing. About XIENCE V XIENCE V
is used to treat coronary artery disease by propping open a
narrowed or blocked artery and releasing the drug, everolimus, in a
controlled manner to prevent the artery from becoming blocked again
following a stent procedure. XIENCE V is built upon Abbott's
market-leading bare metal stent, the MULTI-LINK VISION Coronary
Stent System. The VISION platform is designed to facilitate ease of
delivery, making it easier for physicians to maneuver the stent and
treat the diseased portion of the artery. The XIENCE V stent is
available on both over-the-wire (OTW) and rapid exchange (RX)
delivery systems. Rapid exchange is the most widely used type of
delivery system because it provides physicians additional
flexibility to work as single operators during stent procedures.
Abbott's market-leading XIENCE V drug eluting stent is commercially
available in the United States, Europe and other international
markets. XIENCE V is an investigational device in Japan and is
currently under review by Japan's Ministry of Health, Labour and
Welfare and the Pharmaceuticals and Medical Devices Agency. Abbott
also supplies a private-label version of XIENCE V to Boston
Scientific called the PROMUS Everolimus-Eluting Coronary Stent
System. PROMUS is designed and manufactured by Abbott and supplied
to Boston Scientific as part of a distribution agreement between
the two companies. Everolimus, developed by Novartis Pharma AG, is
a proliferation signal inhibitor, or mTOR inhibitor, licensed to
Abbott by Novartis for use on its drug eluting stents. Everolimus
has been shown to inhibit in-stent neointimal growth in the
coronary vessels following stent implantation, due to its
antiproliferative properties. XIENCE V is indicated for improving
coronary luminal diameter in patients with symptomatic heart
disease due to de novo native coronary artery lesions (lesions less
than or equal to 28 mm) with reference vessel diameters of 2.5 mm
to 4.25 mm. Additional information about XIENCE V, including
important safety information, is available online at
http://www.xiencev.com/ or
http://www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.
About Abbott Vascular Abbott Vascular, a division of Abbott, is one
of the world's leading vascular care businesses. Abbott Vascular is
uniquely focused on advancing the treatment of vascular disease and
improving patient care by combining the latest medical device
innovations with world-class pharmaceuticals, investing in research
and development, and advancing medicine through training and
education. Headquartered in Northern California, Abbott Vascular
offers a comprehensive portfolio of vessel closure, endovascular
and coronary products. About Abbott Abbott is a global, broad-based
health care company devoted to the discovery, development,
manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company
employs more than 72,000 people and markets its products in more
than 130 countries. Abbott's news releases and other information
are available on the company's Web site at http://www.abbott.com/.
* Unless otherwise noted, all event rates and p-values are based on
Kaplan-Meier estimates; p-values are for descriptive purposes only.
** Stent thrombosis rates are based on binary event rates, and
p-values are based on Fisher's Exact Test; p-values are for
descriptive purposes only. *** Subgroup event rates are based on
binary event rates. DATASOURCE: Abbott CONTACT: media, Jonathon
Hamilton, +1-408-624-0314, or Jennie Kim, +1-408-332-4176, or
Financial, John Thomas, +1-847-938-2655, or Tina Ventura,
+1-847-935-9390, all for Abbott Web Site: http://www.abbott.com/
Copyright